Gilead Sciences Ltd. / UKONS
Haemato-Oncology Nurse Masterclass

12:00 – 18:30
Thursday 15th November 2018
The Crowne Plaza Hotel, Glasgow, Scotland

The ‘UKONS / Gilead Sciences Ltd – Haemato-Oncology Nurse Masterclass’ is an afternoon medical education meeting focusing on Chronic Lymphocytic Leukaemia (CLL) and Follicular Lymphoma (FL). The meeting will bring together a notable faculty of oncology experts from across the UK who will preview the latest advances in research, consider the likely impact on the clinic of tomorrow, and discuss and debate the pertinent issues which are affecting the professional community.



Karen CampbellKaren Campbell
Macmillan Associate Professor
Edinburgh Napier University

The full programme can be viewed HERE

Who should attend?
This meeting is ideal for:

  • Nurses
  • Consultants
  • GPs
  • Pharmacists
  • Researchers and
  • Scientists

and any healthcare professionals who have an interest in the future shape and direction of FL & CLL research and treatment.

‘Haemato-Oncology Nurse Masterclass’ (code: 122641) has been approved by the Federation of the Royal Colleges of Physicians of the United Kingdom for 3 category 1 (external) CPD credit(s). Please note, CPD credits obtained through RCP will be accepted by other medical colleges such as the Royal College of Pathologists and the Royal College of Nursing.

When & Where
Thursday 15th November 2018, 12:30 – 18:00
The Crowne Plaza Hotel
Congress Rd,
G3 8QT.
Map here

The meeting costs are underwritten by Gilead Sciences Ltd. and the event is free of charge for healthcare professionals to attend. Places are strictly limited by room capacity.

Date of preparation: June 2019

This activity is intended for medical Haematology/Oncology healthcare professionals, scientists and academics involved in the management of, and research into CAR T-cell therapy in patients with high-grade lymphoid malignancies, specifically relapsed/refractory diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMBCL), as well as those with interest in the wider treatment landscape of haematological malignancies. Data on licensed CAR-T products will be presented.